Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis.
Normal haemostasis is maintained by a controlled balance between coagulation and fibrinolysis, involving thrombin and plasmin the respective key enzymes. Simultaneous evaluation of both enzymes facilitates, therefore, an overall understanding of normal and pathological haemostasis. Combined thrombin and plasmin generation (T/P-G) assays have been recently described, and we have adapted the technique to investigate the interplay between coagulation and fibrinolysis in patients with various haemostatic disorders. Our modified T/P-G was initiated by the addition of a mixture of optimised lower concentrations of tissue factor and tissue-type plasminogen activator. Thrombin generation (TG) and plasmin generation (PG) were monitored simultaneously using individual fluorescent substrates in separate microtitre wells. The relationship between coagulation and fibrinolysis was demonstrated by analysing the effects of thrombin inhibitors, activated protein C and thrombomodulin. The most evident impairments in TG were observed with plasma samples deficient of coagulation factors participating in the prothrombinase complex. Defects in PG were observed with deficiencies of factor (F)V, FX, fibrinogen, and plasminogen. TG appeared to be a prerequisite for the initiation of PG, and overall PG was governed by fibrinogen concentration. TG in patients with haemophilia A correlated with levels of FVIII activity, but there was no significant relationship between PG and FVIII:C, confirming that the abnormal haemostasis in haemophilia A results in a severe imbalance between coagulation and fibrinolysis. The findings demonstrate that global haemostasis depends on a sensitive balance between coagulation and fibrinolysis, and that the modified T/P-G assay could provide an enhanced understanding of haemorrhage and thrombosis in clinical practice.
Keiji Nogami, MD, PhD, Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan, Tel.: +81 744 29 8881, Fax: +81 744 24 9222, E-mail: roc-noga@naramed-u.ac.jp.
Tomoko
T
Matsumoto
Keiji
K
Nogami
Midori
M
Shima
D000347:Afibrinogenemia / Q000378:metabolism*; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D003231:Conjunctivitis / Q000378:metabolism*; D005166:Factor V Deficiency / Q000175:diagnosis / Q000378:metabolism*; D005171:Factor X Deficiency / Q000378:metabolism*; D025461:Feedback, Physiological; D005341:Fibrinolysin / Q000378:metabolism*; D005342:Fibrinolysis; D006467:Hemophilia A / Q000378:metabolism*; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D010958:Plasminogen / Q000172:deficiency* / Q000378:metabolism; D018046:Protein C Inhibitor / Q000378:metabolism; D012873:Skin Diseases, Genetic / Q000378:metabolism*; D013917:Thrombin / Q000378:metabolism*; D018180:Thrombomodulin / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D018046:Protein C Inhibitor; D018180:Thrombomodulin; D010958:Plasminogen; D013925:Thromboplastin; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin
Thrombin generation; coagulation; fibrinolysis; global haemostatic assay; plasmin generation